CXCL1/2/3/5/6/7/8 (receptors are CXCR2) have been demonstrated to be a promoter in tumor angiogenesis within a number of cancer types, including pancreatic cancer, melanoma, and prostate cancer (50, 86). This evidence concerns the gene CXCR2 and prostate cancer.